Life sciences crowdfunding platform Capital Cell launches first UK campaign
Capital Cell, the first pan-European equity crowdfunding platform dedicated to life sciences, has announced the launch of its first active UK campaign on www.capitalcell.co.uk. The platform is raising seed finance for companies across biotechnology and healthcare, with products varying from cancer therapeutics to fertility monitoring devices.
Traditionally, investing in life sciences has been restricted to an exclusive group of sophisticated investors with high technical expertise, but Capital Cell is hoping to address this. Once registered on the platform, both ‘everyday’ and sophisticated investors are able to benefit from the analysis conducted by Capital Cell and invest alongside experts at the same share price. If the companies are successful in achieving their goals the financial rewards for investors can be significant and the social impact can affect the lives of millions.
Capital Cell carries out a unique, multi-step screening process, which includes in-house analysis, crowdsourcing the opinion of a community of ‘BioExperts’ through their BioExpert Network, and working with a sophisticated lead investor. All of the companies planned for UK launch are EIS eligible.
Capital Cell has been successfully funding life sciences companies in Spain for over 2 years. 14 campaigns have been closed, and over €4.4m has been invested through the platform. A national record-breaking €1.2m raise was achieved for a multiple sclerosis therapeutics company. Capitalising on the traction achieved on the continent, Capital Cell has expanded to the UK, accessing the leading biotech market in Europe.
The UK launch of Capital Cell is especially timely given the findings of the recent government commissioned Life Sciences Industrial Strategy Review, highlighting the lack of patient capital to support early-stage companies in scaling. With VC funding in UK early stage ventures plateauing in recent years, equity crowdfunding deals have grown from £28m in 2013 to £245m in 2015. The expectation is that crowdfunding will start to balance the decline of other funding streams, including the European Investment Fund, by acting as a catalyst for growth and innovation in UK life sciences.
Your capital is at risk. Investing in early stage companies involves risks including loss of capital, illiquidity, lack of dividends and dilution. The availability of tax relief (such as EIS) depends on individual investors’ circumstances, and on investee companies’ qualifying status, both of which may be subject to change.
Capital Cell Ltd (FRN 774677) is an Appointed Representative of Larpent Newton & Co Ltd. This message has been approved as a financial promotion by Larpent Newton & Company Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN: 141275). Investments are only offered to Capital Cell registered users.